Bank of Montreal Can Boosts Position in IDEXX Laboratories, Inc. $IDXX

Bank of Montreal Can grew its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 14.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 139,126 shares of the company’s stock after purchasing an additional 18,025 shares during the quarter. Bank of Montreal Can owned approximately 0.17% of IDEXX Laboratories worth $88,886,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the stock. Vanguard Group Inc. increased its stake in shares of IDEXX Laboratories by 0.9% during the 3rd quarter. Vanguard Group Inc. now owns 9,962,025 shares of the company’s stock valued at $6,364,638,000 after acquiring an additional 86,040 shares during the last quarter. Geode Capital Management LLC increased its holdings in IDEXX Laboratories by 2.3% in the 2nd quarter. Geode Capital Management LLC now owns 2,464,290 shares of the company’s stock valued at $1,317,875,000 after purchasing an additional 54,402 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of IDEXX Laboratories by 41.7% during the 3rd quarter. Bank of New York Mellon Corp now owns 2,056,680 shares of the company’s stock valued at $1,313,992,000 after buying an additional 605,290 shares during the period. Principal Financial Group Inc. raised its stake in shares of IDEXX Laboratories by 16.7% during the third quarter. Principal Financial Group Inc. now owns 1,315,722 shares of the company’s stock valued at $840,638,000 after purchasing an additional 187,967 shares during the period. Finally, JPMorgan Chase & Co. increased its stake in IDEXX Laboratories by 60.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 869,930 shares of the company’s stock worth $555,802,000 after buying an additional 326,348 shares during the period. Institutional investors and hedge funds own 87.84% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on IDXX shares. Barclays cut their price target on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a report on Thursday, February 5th. BTIG Research reduced their price objective on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a research report on Tuesday, February 3rd. Weiss Ratings lowered shares of IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, January 29th. Piper Sandler decreased their price target on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research note on Monday, February 9th. Finally, Wall Street Zen cut shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 28th. Seven investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $783.33.

Insider Activity

In other news, CEO Jonathan Jay Mazelsky sold 23,326 shares of the business’s stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $657.55, for a total transaction of $15,338,011.30. Following the sale, the chief executive officer directly owned 83,606 shares in the company, valued at approximately $54,975,125.30. The trade was a 21.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP George Fennell sold 11,345 shares of the stock in a transaction dated Tuesday, February 10th. The stock was sold at an average price of $646.72, for a total transaction of $7,337,038.40. Following the completion of the transaction, the executive vice president directly owned 9,823 shares of the company’s stock, valued at $6,352,730.56. This trade represents a 53.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 45,957 shares of company stock valued at $29,862,109. Corporate insiders own 0.98% of the company’s stock.

IDEXX Laboratories Price Performance

Shares of NASDAQ:IDXX opened at $600.52 on Thursday. The firm has a market cap of $47.81 billion, a price-to-earnings ratio of 45.95, a P/E/G ratio of 3.64 and a beta of 1.66. The company has a current ratio of 1.23, a quick ratio of 0.90 and a debt-to-equity ratio of 0.23. IDEXX Laboratories, Inc. has a 1 year low of $356.14 and a 1 year high of $769.98. The business has a fifty day simple moving average of $662.20 and a 200 day simple moving average of $667.66.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Monday, February 2nd. The company reported $2.92 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.93 by ($0.01). The business had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The firm’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same period in the previous year, the firm posted $2.53 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. As a group, sell-side analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.